Valuation: InspireMD, Inc.

Market Cap 31.9M 27.72M 25.88M 23.76M 44.8M 3.04B 45.58M 305M 120M 1.52B 120M 117M 5B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 31.9M 27.72M 25.88M 23.76M 44.8M 3.04B 45.58M 305M 120M 1.52B 120M 117M 5B EV / Sales 2026 *
3.07x
EV / Sales 2027 * 1.46x
Free-Float
80.17%
Yield 2026 *
-
Yield 2027 * -
1 week-0.51%
Current month+4.77%
1 month-3.65%
3 months-41.79%
6 months-58.45%
Current year-61.74%
1 week 0.65
Extreme 0.65
0.7
1 month 0.65
Extreme 0.65
0.72
Current year 0.63
Extreme 0.63
1.98
1 year 0.63
Extreme 0.63
2.75
3 years 0.63
Extreme 0.63
3.85
5 years 0.63
Extreme 0.63
5.06
10 years 0.63
Extreme 0.63
147,657.17
Manager TitleAgeSince
Chief Executive Officer 62 2019-12-31
Director of Finance/CFO 58 2025-06-24
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 2017-06-01
Director/Board Member 68 2013-02-06
Director/Board Member 62 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
5/11/26 Buy

Chairman

10,000 0.0213%
5/8/26
Osiris Investment Partners LLC
OtherCompany 0 0%
1/15/26 Sell

Executive/Senior Manager

61,194 0.1444%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.51%-74.49%-76.44% 31.9M
-1.82%-3.09%-11.96%+18.39% 131B
-5.47%-5.29%-1.52%+0.89% 13.52B
+0.23%+12.97%+95.38%+129.72% 10.07B
-2.80%+1.43%-42.58%-66.81% 4.73B
-1.16%-3.89%-4.43%+33.02% 2.58B
-0.76%+4.37%+15.70%-47.98% 1.81B
+1.81%+4.56%-23.47%-29.50% 1.71B
+0.48%+3.95%-14.40%-17.45% 1.68B
Average -1.04%+3.84%-6.86%-6.24% 18.56B
Weighted average by Cap. -1.88%+2.23%-5.24%+19.91%

Financials

2026 *2027 *
Net sales 10.38M 9.02M 8.42M 7.73M 14.57M 989M 14.83M 99.26M 38.88M 493M 38.97M 38.11M 1.63B 21.92M 19.05M 17.78M 16.32M 30.78M 2.09B 31.32M 210M 82.12M 1.04B 82.32M 80.5M 3.44B
Net income - -
Net Debt - -
Logo InspireMD, Inc.
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
127
Date Price Change Volume
26-08-04 US$0.6810 0.00% 3,934
26-08-03 US$0.6810 +4.77% 39,041
26-07-31 US$0.6500 -3.25% 72,597
26-07-30 US$0.6718 +0.25% 75,008
26-07-29 US$0.6701 -2.10% 37,247
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6810USD
Average target price
3.667USD
Spread / Average Target
+438.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NSPR Stock